1
0
0
(1 - 18 von 20
)
Establishing long-term efficacy in chronic disease: use of recursive...
doaj.org
ContextEstablishing the long-term benefit of therapy in chronic diseases has been challenging. Long-term studies require non-randomized designs and, thus,
Establishing Long-Term Efficacy in Chronic Disease - PLOSjournals.plos.org › plosone › article › authors › jour...
journals.plos.org
· Karola Beckmann. Affiliation Bayer Schering Pharma AG, Berlin, Germany. Andreas Konieczny. Affiliation Lampe Konieczny & Company, Berlin, ...
Cause of death in MS: long-term follow-up of a randomised ...University of Oxford
ora.ox.ac.uk
— Mark Rametta,9,10,11 Karola Beckmann,9,10,11 Volker Knappertz9,10,11,12. To cite: Goodin DS,. Ebers GC, Cutter G, et al. Cause of death in ...
Oalib search
www.oalib.com
Abstract: Establishing the long-term benefit of therapy in chronic diseases has been challenging. Long-term studies require ...
Altmetric – Establishing Long-Term Efficacy in Chronic Disease: Use...
www.altmetric.com
Goodin DS, Jones J, Li D, Traboulsee A, Reder AT, Beckmann K, Konieczny A, Knappertz V, Douglas S. Goodin, Jason Jones, David Li, Anthony Traboulsee, Anthony T. Reder, Karola Beckmann, Andreas Konieczny, Volker Knappertz, Pablo Villoslada, and the 16-Year Long-Term Follow-up Study Investigators ...
Cause of death in MS: long-term follow-up of a randomised cohort ...cyberleninka.org › article
cyberleninka.org
... Cook,4 Timothy O'Donnell,5 Anthony T Reder,6 Marcelo Kremenchutzky,7 Joel Oger,8 Mark Rametta,9,10,11 Karola Beckmann,9,10,11 Volker Knappertz9,10,11,12.
Establishing long-term efficacy in chronic disease: use of PubMedpubmed.ncbi.nlm.nih.gov › ...
pubmed.ncbi.nlm.nih.gov
Douglas S Goodin , Jason Jones, David Li, Anthony Traboulsee, Anthony T Reder, Karola Beckmann, Andreas Konieczny, Volker Knappertz; 16-Year Long-Term ...
Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive...
plos.figshare.com
Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS
Altmetric – Establishing Long-Term Efficacy in Chronic Disease: Use...
figshare.altmetric.com
Authors. Douglas S. Goodin, Jason Jones, David Li, Anthony Traboulsee, Anthony T. Reder, Karola Beckmann, Andreas Konieczny, Volker Knappertz ...
Long-term follow-up of the original interferon-beta1b trial in multiple ...pure.royalholloway.ac.uk › publications
pure.royalholloway.ac.uk
... David Li, Dawn Langdon, Douglas S Goodin, Christian Wolf, Karola Beckmann, Andreas Konieczny, Investigators of the 16-Year Long-Term Follow-Up Study.
Establishing Long-Term Efficacy in Chronic DiseaseFigshare
figshare.com
posted on , 16:16 authored by Douglas S. Goodin, Jason Jones, David Li, Anthony Traboulsee, Anthony T. Reder, Karola Beckmann, Andreas Konieczny, ...
Establishing long-term efficacy in chronic disease: use of ...Europe PMC
europepmc.org
Douglas S. Goodin, 1 , * Jason Jones, 2 David Li, 3 Anthony Traboulsee, 3 Anthony T. Reder, 4Karola Beckmann, 5 Andreas Konieczny, 6 Volker Knappertz, ...
Establishing Long-Term Efficacy in Chronic Disease - PLOSPLOS
journals.plos.org
von DS Goodin · · Zitiert von: 50 — Karola Beckmann,. Affiliation Bayer Schering Pharma AG, Berlin, Germany. ⨯. Andreas Konieczny,. Affiliation Lampe Konieczny & Company, ... › article
Long-term follow-up of the original interferon-β1b trial in multiple ...www.peeref.com › works
www.peeref.com
George C. Ebers Anthony T. Reder Anthony Traboulsee David Li Dawn Langdon Douglas S. Goodin Christian Wolf Karola Beckmann Andreas Konieczny. 关键词.
Long-term follow-up of the original interferon-beta1b trial in...
pure.royalholloway.ac.uk
... {Douglas S} and Christian Wolf and Karola Beckmann and Andreas Konieczny and {Investigators of the 16-Year Long-Term Follow-Up Study}",. year = "2009",.
Long-term follow-up of the original interferon-β1b trial in ...COEK.INFO
coek.info
... MD6; Christian Wolf, MD7; Karola Beckmann, MSc8; and Andreas Konieczny, MD8; for the Investigators of the 16-Year Long-Term Follow-Up Study* 1Department › ...
Cause of death in patients with multiple sclerosis: The 21-ye
f1000research.com
Access the original poster in full on F1000Research: Cause of death in patients with multiple sclerosis: The 21-year long-term follow-up study
PLOS ONE: Establishing Long-Term Efficacy in Chronic Disease: Use of...
journals.plos.org
Karola Beckmann,. Affiliation Bayer Schering Pharma AG, Berlin, Germany. ⨯. Andreas Konieczny,. Affiliation Lampe Konieczny & Company, ...
Alle Infos zum Namen "Karola Beckmann"
sortiert nach Relevanz / Datum